New podcast up—“What Worries You, Masters You” We review recent news, regulatory and guideline updates from the past week. Studies on MTX use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.https://t.co/jRaLCQAt9K https://t.co/opa22JqU41

Exercise and fibromyalgia? Metanalysis of 18 studies & 1184 pts, comparing aerobic, resistance & stretching. All 3 had large & significant effect on pain (not diff from each other); also improves QOL (possibly depression) https://t.co/RYba99OWCh https://t.co/izpHjeXWCt

EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/6pWc6nEUd9 https://t.co/gGGyzEEh0u

Inferior IL-17 Inhibitor Responses in Psoriatic Women Pooled data from two large (IXE trials show that male patients had greater clinical responses than did female patients with PsA are largely unexplored. Reasons for this is unexplained.https://t.co/OAu6gCweDt https://t.co/lsM6hZUwNQ

Study of IV CTX (n 13) vs mepolizumab (n 7)(MPZ; IL-5 inhib) in severe eosinophilic granulomatosis polyangiitis. BVAS & EOS# equal at mo 1 & 6, but MPZ had better retention(61 vs 5%) & less AEs (29% vs 54%) https://t.co/7s38a67C1r https://t.co/oXLb1ctoc7

New Updated GRAPPA Psoriatic Arthritis Recommendations The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains." A great reference to print & carry.https://t.co/0K8LP3LA9j https://t.co/1fJlzPKLWl

JAMA Clinical Review 15 min podcast on treatment of carpal tunnel syndrome and trigger finger and common hand problems in clinical practice; featuring Drs. Mary M. McDermott, and Kelly Currie https://t.co/IhD6iqVyqC https://t.co/aChPLIbuEu

The EMA's CHMP has positively recommended upadacitinib for use in Non-radiographic axial spondyloarthritis (nr-axSpA) based on Phase 3 SELECT-AXIS 2 study showing superior ASAS40 responses at week 14 https://t.co/uc7oOKglLX https://t.co/yz7M8U3rkk

JAMA Patient Page on "What is Carpal Tunnel Syndrome ? A great patient resource, full read with graphics https://t.co/lL9209YpdL https://t.co/28ceu2obma

🆕🚨Possible future avenues for myositis therapeutics: DM,IMNM&IBM Current treatment options in IIM management 1st line:GC+ Skin➡️MTX/AZR/MMF Muscle➡️AZR/MMF/MTX Lung➡️AZR/MMF Dysphagia/Diaphragmatic weakness➡️IVIG RP-ILD➡️IVIG+CNI+CYC/RTX Calcinosis➡️JAKihttps://t.co/G3vN055Gyq https://t.co/Qy9MULgeMs

Idiopathic inflammatory myopathies, Camille Rasmussen #BJHM #MedEd #FOAMed #Medtwitter #Myopathy #rheumtwitter #MedStudentTwitter https://t.co/dsqwHIAqnX

Are you an Expert in Still's disease, Periodic Fevers, FMF or Autoinflammatory Dz? We will add you to our expert referral listing. DM me to get on the list! https://t.co/hCkC1Yu9Nh

Novel Anti-TNF Shines in Rheumatoid Arthritis Trial A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.https://t.co/fTmWeIrVD5 https://t.co/LPk2Ok2gac

Placebo Works Best in Combination Analysis of two large clinical trial datasets shows that placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis are better when the patient continued background MTX.https://t.co/JmNGRQWv6L https://t.co/77LdcTwCvl

New Updated GRAPPA Psoriatic Arthritis Recommendations The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains."https://t.co/PkDofio1eh https://t.co/kp6UEgwonV

Video: Post Hoc Analysis of the ORAL Surveillance Studyhttps://t.co/PVzfYlzdQa https://t.co/0RpA3CfTEE

Gabapentin Implicated in Overdose Deaths Recent FDA and MMWR warnings suggest that gabapentin was present in almost 10% of US overdose deaths between 2019 & 2020. The report also stated that gabapentin was the cause of the death in half of these cases. https://t.co/ilNAd7ifdZ https://t.co/5GIcySXSDZ

No science to F/U visit scheduling. Study of 114 outpt SpA visits, 34% considered unnecessary (fewer Rx change 15 v 52%) & clinical actions (23 v 63%) visits) vs. "necessary" visits (predict by ASDAS ≥2.1 & PtGA ≥3 >80%). Remote monitoring role? https://t.co/J8TIQRb0LG https://t.co/TCSN0NaeC8